U.S. Markets closed
  • S&P 500

    4,401.46
    -20.84 (-0.47%)
     
  • Dow 30

    35,058.52
    -85.79 (-0.24%)
     
  • Nasdaq

    14,660.58
    -180.14 (-1.21%)
     
  • Russell 2000

    2,191.83
    -25.09 (-1.13%)
     
  • Crude Oil

    71.94
    +0.29 (+0.40%)
     
  • Gold

    1,799.00
    -0.80 (-0.04%)
     
  • Silver

    24.73
    +0.08 (+0.31%)
     
  • EUR/USD

    1.1822
    -0.0004 (-0.0355%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3880
    +0.0002 (+0.0111%)
     
  • USD/JPY

    109.7730
    +0.0060 (+0.0055%)
     
  • BTC-USD

    39,092.03
    +1,451.18 (+3.86%)
     
  • CMC Crypto 200

    898.78
    +22.55 (+2.57%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

·2 min read

Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 30, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Aquestive included data in its New Drug Application ("NDA") submission for Libervant Buccal Film for the management of seizure clusters ("Libervant") that showed a suboptimal drug exposure level for certain weight groups. This inappropriate data lowered the likelihood of the NDA achieving approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Aquestive, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82071